Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SURGERY PARTNERS, INC.

(SGRY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SURGERY PARTNERS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

11/09/2021 | 08:32am EST

Item 1.01 Entry into a Material Definitive Agreement.

On November 8, 2021, Surgery Partners, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with BofA Securities, J.P. Morgan Securities LLC, and Jefferies LLC acting as representatives of the several underwriters (the "Underwriters"), relating to a public offering (the "Offering") of 6,000,000 shares (the "Firm Shares") of the Company's common stock, $0.01 par value per share (the "Common Stock"), at a price to the public of $46.50 per share. In addition, the Company granted the Underwriters an option to purchase up to an additional 900,000 shares (the "Optional Shares" and together with the Firm Shares, the "Shares") of Common Stock at the same price per share as the Firm Shares. Subject to customary closing conditions, the closing of the Offering is expected to take place on November 12, 2021.

The Offering was made pursuant to the Company's effective automatic shelf registration statement on Form S-3, as amended (File No. 333-252399), including the prospectus dated November 8, 2021, as supplemented by the prospectus supplement dated November 8, 2021.

The above description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
  1.1           Underwriting Agreement, dated November 8, 2021, among Surgery
              Partners, Inc. and BofA Securities, J.P. Morgan Securities LLC and
              Jefferies LLC, as representatives of the several underwriters.
  5.1           Opinion of Ropes & Gray LLP.
  23.1          Consent of Ropes & Gray LLP (included in Exhibit 5.1 above)
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about SURGERY PARTNERS, INC.
01/10Surgery Partners Reaffirms 2021 Revenue Growth Guidance; Names David T. Doherty as CFO
MT
01/10SURGERY PARTNERS : REAFFIRMS 2021 AND 2022 FULL YEAR GUIDANCE; DAVID T. DOHERTY TO ASSUME ..
PU
01/10SURGERY PARTNERS : 40th Annual J.P. Morgan Healthcare Conference Presentation
PU
01/10Surgery Partners Reaffirms 2021 and 2022 Full Year Guidance; David T. Doherty to Assume..
AQ
01/10Surgery Partners, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ended December 3..
CI
01/10Surgery Partners, Inc. Announces Executive Changes
CI
01/03SURGERY PARTNERS : Announces Settlement of Derivative Action
PU
01/03Surgery Partners, Inc. to Present at Upcoming Investor Conference
AQ
2021Certain Common stock of Surgery Partners, Inc. are subject to a Lock-Up Agreement Endin..
CI
2021Certain Stock Options of Surgery Partners, Inc. are subject to a Lock-Up Agreement Endi..
CI
More news
Analyst Recommendations on SURGERY PARTNERS, INC.
More recommendations
Financials (USD)
Sales 2021 2 236 M - -
Net income 2021 -56,0 M - -
Net Debt 2021 2 541 M - -
P/E ratio 2021 -57,4x
Yield 2021 -
Capitalization 3 966 M 3 966 M -
EV / Sales 2021 2,91x
EV / Sales 2022 2,67x
Nbr of Employees 9 950
Free-Float 38,7%
Chart SURGERY PARTNERS, INC.
Duration : Period :
Surgery Partners, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURGERY PARTNERS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 45,12 $
Average target price 62,90 $
Spread / Average Target 39,4%
EPS Revisions
Managers and Directors
J. Eric Evans Chief Executive Officer & Director
Thomas F. Cowhey CFO, Principal Accounting Officer & Executive VP
Wayne S. DeVeydt Executive Chairman
Varun Gadhok Chief Information Officer & Senior Vice President
Roxanne Womack Chief Compliance Officer & Senior Vice President